A Phase 1, Open-Label, Parallel Group Trial to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single Intravenous Dose of TAK-954
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2018
At a glance
- Drugs TD 8954 (Primary)
- Indications Gastrointestinal motility disorders
- Focus Pharmacokinetics
- Sponsors Takeda
- 19 Jan 2018 Status changed from not yet recruiting to recruiting.
- 18 Oct 2017 Planned End Date changed from 23 Mar 2018 to 31 Jul 2018.
- 18 Oct 2017 Planned primary completion date changed from 23 Mar 2018 to 31 Jul 2018.